CG Oncology, Inc.
CGONHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CG Oncology, Inc. focuses on Biotechnology services and products. CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. At a $5.49B market cap, CG Oncology, Inc. ranks as a mid-cap company within healthcare. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Market Cap
$5.49B
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
-22.41
EPS (TTM)
$-2.34
EPS (Fwd)
$-2.78
ROE
-20.8%
ROA
-14.4%
Cash
$1.08B
Total Debt
$7.6M
Free CF
-$105.9M
52W Change
134.3%
Annual Financials
Cash vs Debt
With $1.08B in cash and $7.6M in debt, CGON maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$105.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -20.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $191K (2022) to $4.0M (2025), reflecting a 2015% increase over the period.
With a beta below 0.7, CG Oncology, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CGON.